Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Liabilities and Shareholders Equity (2021 - 2025)

Historic Liabilities and Shareholders Equity for InMed Pharmaceuticals (INM) over the last 5 years, with Q4 2025 value amounting to $11.2 million.

  • InMed Pharmaceuticals' Liabilities and Shareholders Equity rose 3162.9% to $11.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $49.4 million, marking a year-over-year increase of 1192.23%. This contributed to the annual value of $15.6 million for FY2025, which is 3177.98% up from last year.
  • According to the latest figures from Q4 2025, InMed Pharmaceuticals' Liabilities and Shareholders Equity is $11.2 million, which was up 3162.9% from $13.4 million recorded in Q3 2025.
  • Over the past 5 years, InMed Pharmaceuticals' Liabilities and Shareholders Equity peaked at $19.4 million during Q4 2021, and registered a low of $8.5 million during Q4 2024.
  • Its 5-year average for Liabilities and Shareholders Equity is $13.6 million, with a median of $13.7 million in 2023.
  • In the last 5 years, InMed Pharmaceuticals' Liabilities and Shareholders Equity tumbled by 4426.72% in 2024 and then surged by 3177.98% in 2025.
  • Quarter analysis of 5 years shows InMed Pharmaceuticals' Liabilities and Shareholders Equity stood at $19.4 million in 2021, then decreased by 12.71% to $16.9 million in 2022, then decreased by 9.84% to $15.3 million in 2023, then plummeted by 44.27% to $8.5 million in 2024, then soared by 31.63% to $11.2 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $11.2 million for Q4 2025, versus $13.4 million for Q3 2025 and $15.6 million for Q2 2025.